Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 229

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 229
---
 further obligations to BofA under the underwriting agreement with respect to the Business Combination with the Company, and no obligations relating to the Business Combination with the Company. 96 BofA declined to act for APx as an advisor in connection with the Business Combination, and BofA has had no role in the preparation of the disclosure that is included in this proxy statement / prospectus, or the underlying business analysis related to the Business Combination. As described above, BofA declined to serve in any capacity in connection with the Business Combination with the Company and agreed to waive its deferred compensation relating to the IPO in connection with the Business Combination with the Company. Accordingly, BofA has not been involved in the Business Combination with the Company, the preparation of any disclosure that is included in this proxy statement/prospectus, or any business analysis underlying such disclosure, and shareholders do not have the benefit of any such involvement. Shareholders and investors should not place any reliance on the fact that BofA was previously involved in the IPO. 97 Unaudited Pro Forma Combined Consolidated Financial Information Introduction OmnigenicsAI is providing the following unaudited pro forma combined consolidated financial information to aid you in your analysis of the financial aspects of the Transactions. The following unaudited pro forma combined statements of financial position as of June 30, 2024, combines the historical unaudited balance sheet of APx as of June 30, 2024 and the historical audited combined statement of financial position of the Company as of June 30, 2024, giving pro forma effect to the Business Combination, as of June 30, 2024. The following unaudited pro forma combined consolidated statements of operations for the year ended June 30, 2024, combine: •the historical audited combined statement of operations of OmnigenicsAI for year ended June30, 2024; and •the historical statement of operations of APx for the twelve -monthperiod ended June30, 2024, using its unaudited statements of operations for the six -monthperiod ended June30, 2024 together with its audited statements of operations for the fiscal year ended December31, 2023, deducting its unaudited statements of operations for the six -monthperiod ended June30, 2023. The unaudited pro forma combined consolidated statement of operations was prepared giving pro forma effect to the Business Combination as if it had occurred on July 1, 2023, the